
Maternal Health Inequities: Improving Access to Postpartum Depression Treatment
Douglas Weber, MD, explains how zuranolone has changed the landscape for postpartum depression treatment, addressing a gap in care within maternal health.
Zuranolone (Zurzuvae; Sage Therapeutics/Biogen), the first oral medication approved by the FDA for
In this episode of
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.